AstraZeneca shareholders approve Alexion acquisition
AstraZeneca
10,656.00p
14:45 07/01/25
-0.52%
-56.00p
AstraZeneca’s acquisition of Alexion Pharmaceuticals is set to close in the third quarter after shareholders voted in favour of the deal.
FTSE 100
8,241.99
14:45 07/01/25
n/a
n/a
FTSE 350
4,538.54
14:45 07/01/25
n/a
n/a
FTSE All-Share
4,494.83
14:45 07/01/25
n/a
n/a
Pharmaceuticals & Biotechnology
20,347.36
14:45 07/01/25
-0.25%
-50.93
Chief executive Pascal Soriot said: "The approval of the acquisition by AstraZeneca shareholders represents a significant step toward combining Alexion's leadership in complement biology and rare diseases with AstraZeneca's expertise in precision medicine and growing presence in immunology.
"We look forward to together advancing life-changing science and bringing even more medicines to patients globally."
The pharmaceuticals giant announced in December 2020 that it had agreed to buy Alexion in a $39bn deal to expand its scientific presence in immunology.